The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment patterns in men with castration-resistant prostate cancer receiving docetaxel.
Keith L. Davis
Research Funding - Bristol-Myers Squibb
Benjamin Gutierrez
Employment or Leadership Position - Bristol-Myers Squibb
Teresa Maria Zyczynski
Employment or Leadership Position - Bristol-Myers Squibb
James A. Kaye
Research Funding - Bristol-Myers Squibb